Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Altamira Therapeutics Ltd CYTOF

Healthcare Biotechnology
Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery... see more

Recent & Breaking News (OTCQB:CYTOF)

Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma

GlobeNewswire November 30, 2022

In Vivo Data Presented at AHA Conference Demonstrates Altamira Therapeutics' SemaPhore mRNA Delivery Platform to Effectively Help Preserve Atherosclerotic Plaque Stability

Accesswire November 22, 2022

Altamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid Event

GlobeNewswire November 10, 2022

Altamira Therapeutics Regains Listing Compliance with NASDAQ Minimum Bid Requirement

GlobeNewswire November 9, 2022

Data Published in Peer-Reviewed Journal Demonstrate Protective Effects of Altamira's Bentrio under Controlled Grass Pollen Exposure

GlobeNewswire November 8, 2022

Altamira Therapeutics Announces Reverse Stock Split

GlobeNewswire October 24, 2022

Altamira Therapeutics Announces Divestiture of Inner Ear Development Assets

GlobeNewswire October 21, 2022

Altamira Therapeutics to Participate at RNA Leaders USA Congress

GlobeNewswire October 13, 2022

Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in Australia

GlobeNewswire October 3, 2022

Altamira Therapeutics Re-launches Bentrio in Europe for Allergic Rhinitis

GlobeNewswire September 27, 2022

Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19

GlobeNewswire September 13, 2022

Altamira Therapeutics to Host Investor Call on September 14th

GlobeNewswire September 8, 2022

Altamira Therapeutics to Participate in the 4th Annual RAS-Targeted Drug Development Summit

GlobeNewswire September 8, 2022

Altamira Therapeutics Provides Business Update

GlobeNewswire August 30, 2022

Altamira Therapeutics' CEO Interviewed by Proactive Investors to Discuss its Pipeline of RNA Therapeutics and Ongoing Strategic Transformation

GlobeNewswire August 3, 2022

Altamira Therapeutics Completes Interim Sample Size Analysis of COVAMID Trial with Bentrio in Acute COVID-19

GlobeNewswire August 1, 2022

Altamira Therapeutics' Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed Journal

GlobeNewswire July 28, 2022

Altamira Therapeutics to Develop Novel Generation of Rheumatoid Arthritis Therapeutics Based on its Proprietary OligoPhore Delivery Platform and siRNA Targeting Key Inflammation Checkpoint

GlobeNewswire July 25, 2022

Altamira Therapeutic's SemaPhore Platform Shown Particularly Effective in Intracellular mRNA Delivery for Cancer Therapy

GlobeNewswire July 19, 2022

Altamira Therapeutic's RNA Delivery Platform Shown to be an Effective Treatment for Abdominal Aortic Aneurysm as Published in Peer-Reviewed Journal

Accesswire July 12, 2022